G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease
- PMID: 24976908
- PMCID: PMC4072826
- DOI: 10.4330/wjc.v6.i6.367
G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease
Abstract
Coronary heart disease (CHD) continues to be the greatest mortality risk factor in the developed world. Estrogens are recognized to have great therapeutic potential to treat CHD and other cardiovascular diseases; however, a significant array of potentially debilitating side effects continues to limit their use. Moreover, recent clinical trials have indicated that long-term postmenopausal estrogen therapy may actually be detrimental to cardiovascular health. An exciting new development is the finding that the more recently discovered G-protein-coupled estrogen receptor (GPER) is expressed in coronary arteries-both in coronary endothelium and in smooth muscle within the vascular wall. Accumulating evidence indicates that GPER activation dilates coronary arteries and can also inhibit the proliferation and migration of coronary smooth muscle cells. Thus, selective GPER activation has the potential to increase coronary blood flow and possibly limit the debilitating consequences of coronary atherosclerotic disease. This review will highlight what is currently known regarding the impact of GPER activation on coronary arteries and the potential signaling mechanisms stimulated by GPER agonists in these vessels. A thorough understanding of GPER function in coronary arteries may promote the development of new therapies that would help alleviate CHD, while limiting the potentially dangerous side effects of estrogen therapy.
Keywords: Atherosclerosis; Coronary arteries; Estrogen; G-1; G-protein-coupled estrogen receptor.
Figures

Similar articles
-
Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle.Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E882-8. doi: 10.1152/ajpendo.00037.2011. Epub 2011 Jul 26. Am J Physiol Endocrinol Metab. 2011. PMID: 21791623 Free PMC article.
-
Estrogens and Coronary Artery Disease: New Clinical Perspectives.Adv Pharmacol. 2016;77:307-60. doi: 10.1016/bs.apha.2016.05.003. Epub 2016 Jun 29. Adv Pharmacol. 2016. PMID: 27451102 Review.
-
The activation of G protein-coupled estrogen receptor induces relaxation via cAMP as well as potentiates contraction via EGFR transactivation in porcine coronary arteries.PLoS One. 2018 Jan 23;13(1):e0191418. doi: 10.1371/journal.pone.0191418. eCollection 2018. PLoS One. 2018. PMID: 29360846 Free PMC article.
-
GPER: a novel target for non-genomic estrogen action in the cardiovascular system.Pharmacol Res. 2013 May;71:53-60. doi: 10.1016/j.phrs.2013.02.008. Epub 2013 Mar 4. Pharmacol Res. 2013. PMID: 23466742 Review.
-
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity.J Endocrinol. 2015 Oct;227(1):61-9. doi: 10.1530/JOE-15-0257. Epub 2015 Aug 24. J Endocrinol. 2015. PMID: 26303299 Free PMC article.
Cited by
-
Activation of GPR30 with G1 inhibits oscillatory shear stress-induced adhesion of THP-1 monocytes to HAECs by increasing KLF2.Aging (Albany NY). 2021 Apr 19;13(8):11942-11953. doi: 10.18632/aging.202897. Epub 2021 Apr 19. Aging (Albany NY). 2021. PMID: 33875621 Free PMC article.
-
Activation of GPER ameliorates experimental pulmonary hypertension in male rats.Eur J Pharm Sci. 2017 Jan 15;97:208-217. doi: 10.1016/j.ejps.2016.11.009. Epub 2016 Nov 9. Eur J Pharm Sci. 2017. PMID: 27836751 Free PMC article.
-
Cardioprotection and neurobehavioral impact of swimming training in ovariectomized rats.Geroscience. 2025 Apr;47(2):2317-2334. doi: 10.1007/s11357-024-01422-7. Epub 2024 Nov 11. Geroscience. 2025. PMID: 39527177 Free PMC article.
-
G protein-coupled estrogen receptor 1 as a novel regulator of blood pressure.Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F612-F617. doi: 10.1152/ajprenal.00045.2020. Epub 2020 Sep 7. Am J Physiol Renal Physiol. 2020. PMID: 32893662 Free PMC article. Review.
-
Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344×Brown Norway Female Rat.J Gerontol A Biol Sci Med Sci. 2017 Feb;72(2):152-162. doi: 10.1093/gerona/glw045. Epub 2016 Mar 22. J Gerontol A Biol Sci Med Sci. 2017. PMID: 27006078 Free PMC article.
References
-
- Mackenzie J. Irritation of the sexual apparatus as an etiological factor in the production of nasal disease. Am J Med Sci. 1884;88:360–365.
-
- Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461. - PubMed
-
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed
-
- Raddino R, Manca C, Poli E, Bolognesi R, Visioli O. Effects of 17 beta-estradiol on the isolated rabbit heart. Arch Int Pharmacodyn Ther. 1986;281:57–65. - PubMed
-
- Santos RL, Marin EB, Gonçalves WL, Bissoli NS, Abreu GR, Moysés MR. Sex differences in the coronary vasodilation induced by 17 β-oestradiol in the isolated perfused heart from spontaneously hypertensive rats. Acta Physiol (Oxf) 2010;200:203–210. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources